VMI:NYSEValmont Industries, Inc. Analysis
Data as of 2026-06-10 - not real-time
$512.25
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Valmont Industries is trading at $512.25, comfortably above its 50‑day SMA of 485.00 and 200‑day SMA of 431.48, but slightly under the 20‑day SMA of 521.31, suggesting short‑term price pressure. The stock sits near a technical support zone at 485.29 with resistance around 548.90, while volume has been trending upward and the 30‑day volatility is elevated at 27.5%, reflecting a fairly active market. Momentum indicators are mixed: the RSI of 48.8 points to a neutral stance, yet the MACD histogram is negative (-2.75) and the signal line signals bearishness, tempering the bullish trend label. On the fundamentals side, VMI posted $4.16 B in revenue with a 6.2% growth rate, and its forward EPS of 25.45 implies a forward P/E of 20.1, a notable improvement over the trailing P/E of 28.5. Margins remain solid (gross 30.4%, operating 15.0%) and cash flow is healthy, supporting a modest dividend yield of 0.54% with a low payout ratio of 15.6%. However, the DCF‑derived fair value of $124.94 suggests the market price is significantly overvalued, a view reinforced by a beta of 1.28 and a max drawdown of nearly 20%. Analyst consensus is a “Buy” with a mean target of $545.25, indicating expectations for upside limited to roughly 6% above current levels.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price near technical support with increasing volume
- Bearish MACD histogram offset by bullish trend direction
- Neutral RSI indicating limited near‑term upside
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Improving forward earnings and lower forward P/E
- Steady revenue growth and solid operating margins
- Analyst consensus and modest upside potential
Long Term
> 3 yearsNeutral
Model confidence: 5/10
Key Factors
- Sustainable dividend with low payout ratio
- Exposure to infrastructure and renewable‑energy markets
- Significant valuation gap relative to DCF fair value
Key Metrics & Analysis
Financial Health
Revenue Growth6.20%
Profit Margin8.91%
P/E Ratio28.5
ROE22.19%
ROA10.08%
Debt/Equity54.96
P/B Ratio6.1
Op. Cash Flow$494.8M
Free Cash Flow$187.2M
Industry P/E29.5
Technical Analysis
TrendBullish
RSI48.8
Support$485.29
Resistance$548.90
MA 20$521.31
MA 50$485.00
MA 200$431.48
MACDBearish
VolumeIncreasing
Fear & Greed Index81.75
Valuation
Fair Value$124.94
Target Price$545.25
Upside/Downside6.44%
GradeOvervalued
TypeGrowth
Dividend Yield0.54%
Risk Assessment
Beta1.28
Volatility27.50%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.